Novel Palladium Complex: Cytotoxicity against Cisplatin-resistant K562 Cells

Authors

  • Ali Jahanian-Najafabadi Department of Pharmaceutical Biotechnology, School of Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran.
  • Fatemeh Rouhani Department of Pharmaceutical Chemistry, School of Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran.
  • Hojjat Sadeghi-Aliabadi Department of Pharmaceutical Chemistry, School of Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran.
  • Kazem Karami Department of Chemistry, Isfahan University of Technology, Isfahan, Iran.
  • Mina Mirian Department of Pharmaceutical Biotechnology, School of Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran.
Abstract:

Today, development of resistance to anticancer drugs (including cisplatin) is noticed as a major problem. Recently several studies demonstrated that palladium complexes showed remarkable cytotoxic effects against K562 cell line and could be used efficiently for treatment of many human cancers including leukemia. Hereof, K562 cells were made resistant to cisplatin using increasing concentration of cisplatin up to 4.5 , and then cytotoxic effect of synthesized palladium complex was evaluated on this sub-line using MTT assay. Annexin V/PI staining using flow cytometry and scanning electron microscopy (SEM) were performed to find out the mechanism of the observed cytotoxicity. Results indicated that tested compounds had a noticeable cytotoxic effect on K562 cells 80 times more than cisplatin. Palladium complex also showed significant cytotoxicity on resistant K562 sub-line. Flow cytometry and SEM results revealed that these compounds exert their cytotoxic effect via apoptosis and it could be concluded that the novel synthesized palladium complex might be a good candidate for replacing cisplatin in case of treatment of cisplatin resistant tumors.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

Enhanced cytotoxicity of photoexcited fullerene C60 and cisplatin combination against drug-resistant leukemic cells.

AIM To evaluate the viability of leukemic cells sensitive (L1210S) and resistant (L1210R) to cisplatin, ROS production and free cytosolic Ca(2+) concentration under treatment with cisplatin or its combination with photoexcited fullerene C60. METHODS Cell viability was assessed by the MTT reduction assay. Light-emitting diode lamp (2.45 J/cm(2)) was used for photoexcitation of intracellular ac...

full text

Proteasome Inhibitor YSY01A Enhances Cisplatin Cytotoxicity in Cisplatin-Resistant Human Ovarian Cancer Cells

Cisplatin is one of the most common drugs used for treatment of solid tumors such as ovarian cancer. Unfortunately, the development of resistance against this cytotoxic agent limits its clinical use. Here we report that YSY01A, a novel proteasome inhibitor, is capable of suppressing survival of cisplatin-resistant ovarian cancer cells by inducing apoptosis. And YSY01A treatment enhances the cyt...

full text

Tangeretin protects renal tubular epithelial cells against experimental cisplatin toxicity

Objective(s): Cisplatin is an effective antineoplastic agent; its clinical utility, however, is limited by a few salient toxic side effects like nephrotoxicity. This study aimed to determine the potential protective effects of tangeretin, a citrus-derived flavonoid, against renal tubular cell injury in cisplatin-induced renal toxicity of rats.Materials and Methods: Tangeretin was injected intra...

full text

Lipocalin2 Protects Human Embryonic Kidney Cells against Cisplatin–Induced Genotoxicity

Cisplatin is one of the most useful chemotherapeutics which performs its cytotoxic effectvia accumulation of platinum resulting in oxidative stress, and destruction of cell DNA. Thiscould probably cause secondary cancers in healthy tissues. Lipocalin2 (Lcn2) is a protein whichits expression is increased in oxidative stresses. Therefore, the present study was performedto evaluate the protective ...

full text

Lipocalin2 Protects Human Embryonic Kidney Cells against Cisplatin–Induced Genotoxicity

Cisplatin is one of the most useful chemotherapeutics which performs its cytotoxic effectvia accumulation of platinum resulting in oxidative stress, and destruction of cell DNA. Thiscould probably cause secondary cancers in healthy tissues. Lipocalin2 (Lcn2) is a protein whichits expression is increased in oxidative stresses. Therefore, the present study was performedto evaluate the protective ...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 18  issue 3

pages  1323- 1331

publication date 2019-07-01

By following a journal you will be notified via email when a new issue of this journal is published.

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023